Literature DB >> 28670391

URI promotes the migration and invasion of human cervical cancer cells potentially via upregulation of vimentin expression.

Zhonghai Xu1, Huiqin Bian1, Fei Zhang1, Rui Mi1, Qian Wang1, Yaojuan Lu1, Qiping Zheng1, Junxia Gu1.   

Abstract

URI is known to act as an oncoprotein in several tumors. Our previous studies have shown that URI is associated with the migration process in cervical and gastric cancer cells, but the mechanisms remain to be determined. Given the fact that URI positively regulates vimentin expression, we therefore investigated how URI regulated vimentin expression affects the migration and invasion of cells from two human cervical cancer cell lines HeLa and C33A, which differentially express URI. We have shown that knock-down of URI in HeLa cells using URI siRNA caused decreased vimentin mRNA and protein levels along with attenuated cell motility. Meanwhile, overexpression of URI by transfection of PCMV6-URI in C33A cells resulted in increased vimentin expression and enhanced cell migration and invasion. We have also used TGF-β to induce vimentin expression, which enhanced the cell migration and invasion abilities affected by URI, while inhibition of vimentin by siRNA attenuated URI's effect on cell migration and invasion. In addition, we have performed luciferase reporter and ChIP assays, and the results support that URI indirectly enhances the activity of vimentin promoter. Taken together, our results suggest that URI plays essential roles in the migration and invasion of human cervical cancer cells, possibly via targeting vimentin expression.

Entities:  

Keywords:  HeLa and C33A cell lines; TGF-β; URI; migration and invasion; vimentin

Year:  2017        PMID: 28670391      PMCID: PMC5489903     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  31 in total

Review 1.  TGF-beta and epithelial-to-mesenchymal transitions.

Authors:  Jiri Zavadil; Erwin P Böttinger
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

Review 2.  The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.

Authors:  Munetaka Takekuma; Yuka Kasamatsu; Nobuhiro Kado; Shiho Kuji; Aki Tanaka; Nobutaka Takahashi; Masakazu Abe; Yasuyuki Hirashima
Journal:  J Obstet Gynaecol Res       Date:  2017-02-11       Impact factor: 1.730

3.  URI is an oncogene amplified in ovarian cancer cells and is required for their survival.

Authors:  Jean-Philippe Theurillat; Stefan Christian Metzler; Nico Henzi; Nabil Djouder; Marianne Helbling; Anna-Kathrin Zimmermann; Francis Jacob; Alex Soltermann; Rosmarie Caduff; Viola Heinzelmann-Schwarz; Holger Moch; Wilhelm Krek
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

Review 4.  Novel functions of vimentin in cell adhesion, migration, and signaling.

Authors:  Johanna Ivaska; Hanna-Mari Pallari; Jonna Nevo; John E Eriksson
Journal:  Exp Cell Res       Date:  2007-04-14       Impact factor: 3.905

5.  URI promotes gastric cancer cell motility, survival, and resistance to adriamycin in vitro.

Authors:  Xiaoxia Hu; Fei Zhang; Dongwei Luo; Na Li; Qian Wang; Zhonghai Xu; Huiqin Bian; Yuting Liang; Yaojuan Lu; Qiping Zheng; Junxia Gu
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

Review 6.  A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.

Authors:  David Jenkins
Journal:  Gynecol Oncol       Date:  2008-07-23       Impact factor: 5.482

7.  Association of Vimentin overexpression and hepatocellular carcinoma metastasis.

Authors:  Liang Hu; Sze Hang Lau; Chi-Hung Tzang; Jian-Ming Wen; Weisheng Wang; Dan Xie; Minghui Huang; Yi Wang; Meng-Chao Wu; Jie-Fu Huang; Wei-Fen Zeng; Jonathan S T Sham; Mengsu Yang; Xin-Yuan Guan
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

Review 8.  Epithelial-mesenchymal transition in tumor metastasis.

Authors:  Kay T Yeung; Jing Yang
Journal:  Mol Oncol       Date:  2016-12-09       Impact factor: 6.603

9.  Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.

Authors:  Samy Lamouille; Rik Derynck
Journal:  J Cell Biol       Date:  2007-07-23       Impact factor: 10.539

10.  Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression.

Authors:  Z Zelenko; E J Gallagher; A Tobin-Hess; V Belardi; R Rostoker; J Blank; Y Dina; D LeRoith
Journal:  Oncogene       Date:  2016-08-29       Impact factor: 9.867

View more
  2 in total

1.  Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer.

Authors:  Toyoharu Kamibeppu; Koji Yamasaki; Kozue Nakahara; Takahiro Nagai; Naoki Terada; Hiromasa Tsukino; Shoichiro Mukai; Toshiyuki Kamoto
Journal:  Res Rep Urol       Date:  2018-10-03

2.  TMEFF2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway.

Authors:  Hongchao Han; Zhilin Zhan; Jie Xu; Zhenshun Song
Journal:  Onco Targets Ther       Date:  2019-12-23       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.